Pfizer Gains Phase II Skin Fibrosis Drug with Excaliard Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 12 (Table of Contents)
Published: 22 Dec-2011
DOI: 10.3833/pdr.v2011.i12.1637 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Attracted by positive Phase II results for the company’s lead antifibrotic antisense drug candidate EXC 001, Pfizer has bought privately held Excaliard Pharmaceuticals, a spin-off of Isis Pharmaceuticals, for an undisclosed sum...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS